Kadri Altundag
AuthID: R-00G-Q8B
1
TITLE: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
AUTHORS: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLISHED: 2015, SOURCE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, ISSUE: 9
AUTHORS: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLISHED: 2015, SOURCE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, ISSUE: 9
INDEXED IN: 
WOS 
CrossRef
WOS CrossRef